| FY 2021 | Est. | Actual | Surprise | ||||
|---|---|---|---|---|---|---|---|
| EPS | (EXPECTED)2022-04-09 | ||||||
| REV | |||||||
| Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
|---|
You can purchase shares of Celyad Oncology (NASDAQ: CYAD) through any online brokerage.
Other companies in Celyad Oncology’s space includes: Anixa Biosciences (NASDAQ:ANIX), Cabaletta Bio (NASDAQ:CABA), Evaxion Biotech (NASDAQ:EVAX), Gemini Therapeutics (NASDAQ:GMTX) and Genprex (NASDAQ:GNPX).
The latest price target for Celyad Oncology (NASDAQ: CYAD) was reported by Wells Fargo on January 11, 2022. The analyst firm set a price target for 11.00 expecting CYAD to rise to within 12 months (a possible 179.19% upside). 4 analyst firms have reported ratings in the last year.
The stock price for Celyad Oncology (NASDAQ: CYAD) is $3.94 last updated Fri Jan 21 2022 21:00:03 GMT+0000 (Coordinated Universal Time).
There are no upcoming dividends for Celyad Oncology.
Celyad Oncology’s $FY earnings are confirmed for after-market on April 9, 2022.
There is no upcoming split for Celyad Oncology.
Celyad Oncology is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.